National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 46040 [2015-18874]
Download as PDF
<![CDATA[
46040
Federal Register / Vol. 80, No. 148 / Monday, August 3, 2015 / Notices
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Shiv A. Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220,
MSC 7852, Bethesda, MD 20892, 301–443–
5779, prasads@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS).
Dated: July 28, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–18875 Filed 7–31–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Science Moving TowArds Research
Translation and Therapy (SMARTT),
Coordinating Center—Program Extension.
Date: August 25, 2015.
Time: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7185, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301–435–0725,
kristen.page@nih.gov.
VerDate Sep<11>2014
18:35 Jul 31, 2015
Jkt 235001
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Science Moving TowArds Research
Translation and Therapy (SMARTT),
Biologics Production Facility (PF), Program
Extension.
Date: August 25, 2015.
Time: 3:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7185, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301–435–0725,
kristen.page@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Science Moving TowArds Research
Translation and Therapy (SMARTT), NonBiological Production Facility (PF), Program
Extension.
Date: August 25, 2015.
Time: 4:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7185, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301–435–0725,
kristen.page@nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute, Special Emphasis Panel,
Science Moving TowArds Research
Translation and Therapy (SMARTT),
Pharmacology and Toxicology, Program
Extension.
Date: August 25, 2015.
Time: 4:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7185, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301–435–0725,
kristen.page@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: July 28, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–18874 Filed 7–31–15; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00109
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
SUMMARY:
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 80, Number 148 (Monday, August 3, 2015)]
[Notices]
[Page 46040]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18874]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel, Science Moving TowArds Research Translation
and Therapy (SMARTT), Coordinating Center--Program Extension.
Date: August 25, 2015.
Time: 3:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301-
435-0725, kristen.page@nih.gov.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Science Moving TowArds Research Translation
and Therapy (SMARTT), Biologics Production Facility (PF), Program
Extension.
Date: August 25, 2015.
Time: 3:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301-
435-0725, kristen.page@nih.gov.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Science Moving TowArds Research Translation
and Therapy (SMARTT), Non- Biological Production Facility (PF),
Program Extension.
Date: August 25, 2015.
Time: 4:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301-
435-0725, kristen.page@nih.gov.
Name of Committee: National Heart, Lung, and Blood Institute,
Special Emphasis Panel, Science Moving TowArds Research Translation
and Therapy (SMARTT), Pharmacology and Toxicology, Program
Extension.
Date: August 25, 2015.
Time: 4:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301-
435-0725, kristen.page@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: July 28, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-18874 Filed 7-31-15; 8:45 am]
BILLING CODE 4140-01-P
